A study published in the Journal of the American Medical Association shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.

Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration to help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women.

OncoCyte Corporation, a developer of novel tests for the early diagnosis and management of lung cancer, announced a definitive agreement to acquire Razor Genomics.